Bayer Offers $2.9B For Cancer Drugmaker Algeta

Law360, New York (December 19, 2013, 4:49 PM EST) -- Norwegian cancer drugmaker Algeta ASA has preliminarily agreed to a takeover offer from Bayer AG after the German drug and chemical company upped its offer to value the company at almost $2.9 billion, the companies said Thursday.

The Algeta board of directors has agreed to Bayer’s takeover offer of 362 kroner ($58.87) per share in cash, which values Algeta at approximately 17.6 billion kroner ($2.86 billion), the companies said. The offer price represents a 37 percent premium over the company’s closing price Nov. 25, the day...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.